NCT01360255View on ClinicalTrials.gov

AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2015

Study Completion Date

November 15, 2015

Conditions
Hepatocellular Carcinoma
Trial Locations (1)

79106

University Medical Center Freiburg, Freiburg im Breisgau

Sponsors

Collaborators (1)

Wako Diagnostics
All Listed Sponsors
collaborator

Wako Diagnostics

INDUSTRY

lead

University Hospital Freiburg

OTHER

NCT01360255 - AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE) | Biotech Hunter | Biotech Hunter